Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Age does not appear to have a clinically significant impact on the safety and efficacy of rivaroxaban, according to a review published in the journal Current Medical Research and Opinion.
To better understand the impact of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban, researchers reviewed available literature on this oral anticoagulant in both healthy older subjects and those with cardiovascular conditions enrolled in clinical trials; real-world evidence studies were also included.
Results showed that among healthy older adults, age had no clinically relevant effect on the drug’s pharmacokinetics and pharmacodynamics; in studies involving older patients with thromboembolic diseases, a moderate effect on rivaroxaban clearance was noted but was not considered clinically significant. In addition, data from large Phase 3 studies showed that treatment with rivaroxaban was found to be safe and effective in older patients when compared with the overall population; real-world studies further confirmed these results, according to the authors.
“A favorable clinical profile with rivaroxaban was observed across age subgroups, supporting the premise that dosing in older adults does not necessitate adjustment,” the authors concluded.
For more information visit tandfonline.com.
This article originally appeared on MPR
